Literature DB >> 28678431

Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis.

Yuji Sakuma1.   

Abstract

Lung adenocarcinoma cells with activating epidermal growth factor receptor (EGFR) mutations are highly dependent upon EGFR signaling for survival and undergo apoptosis when EGFR signaling is inhibited by tyrosine kinase inhibitor (TKI) treatment. Paradoxically, EGFR-mutant lung adenocarcinomas have subpopulations of cells that can survive independently of activated EGFR. Such EGFR-independent EGFR-mutant cancer cells include cells that have undergone epithelial-to-mesenchymal transition (EMT) or transformed to small cell lung cancer, which almost completely lack EGFR dependency. The presence of such cells suggests that EGFR TKIs cannot eradicate EGFR-mutant lung adenocarcinoma cells. However, little is known about whether and to what extent normal peripheral lung epithelial cells, not lung adenocarcinoma cells, can undergo EMT. We have recently reported that normal peripheral lung epithelial cells can undergo dynamic EMT within 72 h in response to transforming growth factor-β signaling. This finding reinforced the hypothesis that alveolar epithelial cells that have undergone EMT contribute to the formation of fibroblastic foci, the leading edge of fibrotic destruction in lungs affected by idiopathic pulmonary fibrosis. This review focuses on the role of EMT in neoplastic and non-neoplastic peripheral lung epithelial cells. .
© 2017 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  EGFR mutation; autophagy; epithelial-to-mesenchymal transition (EMT); fibroblastic foci (FF); idiopathic pulmonary fibrosis (IPF); lung adenocarcinoma

Mesh:

Substances:

Year:  2017        PMID: 28678431     DOI: 10.1111/pin.12553

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  12 in total

1.  Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Authors:  P Comeglio; S Filippi; E Sarchielli; A Morelli; I Cellai; C Corno; A Pini; L Adorini; G B Vannelli; M Maggi; L Vignozzi
Journal:  J Endocrinol Invest       Date:  2018-06-19       Impact factor: 4.256

2.  The A2B Adenosine Receptor Modulates the Epithelial- Mesenchymal Transition through the Balance of cAMP/PKA and MAPK/ERK Pathway Activation in Human Epithelial Lung Cells.

Authors:  Chiara Giacomelli; Simona Daniele; Chiara Romei; Laura Tavanti; Tommaso Neri; Ilaria Piano; Alessandro Celi; Claudia Martini; Maria L Trincavelli
Journal:  Front Pharmacol       Date:  2018-01-31       Impact factor: 5.810

3.  Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.

Authors:  Toshiyuki Sumi; Sachie Hirai; Miki Yamaguchi; Yusuke Tanaka; Makoto Tada; Gen Yamada; Tadashi Hasegawa; Yohei Miyagi; Toshiro Niki; Atsushi Watanabe; Hiroki Takahashi; Yuji Sakuma
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

4.  Astragaloside IV modulates TGF-β1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis.

Authors:  Weibin Qian; Xinrui Cai; Qiuhai Qian; Wei Zhang; Dongli Wang
Journal:  J Cell Mol Med       Date:  2018-07-04       Impact factor: 5.310

5.  Comparisons of cancer-associated fibroblasts in the intratumoral stroma and invasive front in colorectal cancer.

Authors:  Gyung Mo Son; Myeong-Sook Kwon; Dong-Hoon Shin; Nari Shin; Dongryeol Ryu; Chi-Dug Kang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial-mesenchymal transition by competitively binding miR-141-3p.

Authors:  Weibin Qian; Xinrui Cai; Qiuhai Qian; Wei Peng; Jie Yu; Xinying Zhang; Li Tian; Can Wang
Journal:  Cell Death Dis       Date:  2019-02-12       Impact factor: 8.469

7.  Increased Regeneration Following Stress-Induced Lung Injury in Bleomycin-Treated Chimeric Mice with CD44 Knockout Mesenchymal Cells.

Authors:  Dmytro Petukhov; Mark Richter-Dayan; Zvi Fridlender; Raphael Breuer; Shulamit B Wallach-Dayan
Journal:  Cells       Date:  2019-10-07       Impact factor: 6.600

8.  Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation.

Authors:  Ling Peng; Li Wen; Qing-Feng Shi; Feng Gao; Bin Huang; Jie Meng; Cheng-Ping Hu; Chang-Ming Wang
Journal:  Cell Death Dis       Date:  2020-11-13       Impact factor: 8.469

Review 9.  Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.

Authors:  Ana I Velazquez; Caroline E McCoach
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

10.  The Association between Epidermal Growth Factor Receptor (EGFR) Gene Polymorphisms and Lung Cancer Risk.

Authors:  Nabil A Bashir; Entesar S Ragab; Omar F Khabour; Basheer Y Khassawneh; Mahmoud A Alfaqih; Jafar A Momani
Journal:  Biomolecules       Date:  2018-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.